View on market: Stay Cautious, be with quality business:

Asia stocks and U.S. futures slid Monday as surging energy prices cemented worries about inflation, sending bond yields higher. Equities fell in Japan and South Korea. Australia rose. U.S. contracts dipped after Wall Street stocks advanced on Friday, with the S&P 500 chalking its best week since July as earnings buoyed sentiment. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, rose 0.17% to 18,435 as of 8:00 a.m.

Economic Calender:

  • INR:  M3 Money Supply on 20th October, 2021.
  • INR:  Bank Loan & Deposit Growth on 22th October, 2021.
  • USD: Industrial Production (YoY) (Sep) on 18th October, 2021.
  • USD: Building Permits (MoM) (Sep) on 19th October, 2021.

Earnings: Ultratech Cement, L&T Infotech, Hatsun Agro Product, Route Mobile, Craftsman Automation, Alok Industries, Tata Coffee.


HDFC Bank Q2FY22 (Standalone): NII up 12% at Rs 17,684 crore Vs Rs 15,776.4 crore (YoY) Net profit up 17.6% at Rs 8,834 crore Vs Rs 7,513 crore (YoY) GNPA at 1.35% Vs 1.47% (QoQ) NNPA at 0.40% Vs 0.48% (QoQ) Total provisions for the bank rose 6% YoY to Rs 3,925 crore Total deposits stood at Rs 14.06 lakh crore, up 14.4% YoY.

Avenue Supermarts Q2FY22 (Consolidated, YoY): Revenue up 47% at Rs 7,788.94 crore Vs Rs 5,306.20 crore Net profit up 1.10 times at Rs 417.79 crore Vs Rs 198.55 crore Ebitda up 1.03 times at Rs 668.58 crore Vs Rs 329.5 crore Margin at 8.58% Vs 6.21%

Brokerage Radar:

CLSA ON HDFC BANK: Maintain buy at the price of Rs 1687 for the target price of Rs 2025. Q2 strong with lower slippage than expected. Growth improved especially in NIM Accretive segments. Addl restructuring of 1.2% higher than expected. Rs 9,200 Cr contingency provisions provides comfort on normalising credit costs Commentary indicated retail/commercial growth will continue to accelerate expect an 18% earnings CAGR over FY21-24.

International Markets:

U.S & Europe

Particulars 15th Oct Chg Chg(%)
Nasdaq 14,897.34 73.91 0.50
Dow 35,294.76 382.20 1.09
FTSE 7,234.03 26.32 0.37
CAC 6,727.52 42.31 0.63
DAX 15,587.36 124.64 0.81
Dow Fut.* 35,190.00 19.00 0.05

Asian markets:

Particulars 18th Oct Chg Chg(%)
SGX Nifty 18,435.00 31.00 0.17
Nikkei 28,982.38 -86.25 -0.30
Straits Times 3,166.45 -7.46 -0.24
Hang Seng 25,215.38 -115.58 -0.46
Shanghai 3,548.47 -23.90 -0.67

ADR Watch:

Particulars 15th Oct Chg Chg(%)
Dr Reddy 66.01 0.55 0.84
HDFC Bank 75.76 0.08 0.11
ICICI Bank 19.45 0.08 0.41
Infosys 23.38 0.67 2.95
Tata Motor 34.19 0.26 0.77
Wipro 9.91 0.15 1.54

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR 75.34 -0.19
Brent 85.68  0.95
Gold 1770.95 0.15
Silver</td 23.438 0.38


Particulars 14th Oct 13th Oct
FIIs 1681.60 937.31
DIIs -1750.59 -431.72

News Update:

Coal India: The company has temporarily stopped supplies to industrial users as the energy crisis in India escalates. The move to prioritize supplies to power plants is aimed at helping boost depleted inventories that are putting continued operations at risk. But it could worsen the situation for other industries such as aluminum smelters, cement producers and steel mills.

Lupin: Lupin Pharmaceuticals Inc. has voluntarily recalled lrbesartan tablets and lrbesartan and Hydrochlorothiazide tablets in the U.S. due to the presence of an impurity called N-nitrosolrbesartan. Some tested API batches were above the specification limit for the impurity, the company said. Lupin discontinued the marketing of these tablets in January 2021.

Dr. Reddy’s Laboratories: Exelixis Inc has in-licensed second anti-cancer compound from Aurigene Discovery following U.S. FDA acceptance of lnvestigational New Drug application for phase 1 clinical trial in Non-Hodgkin’s Lymphoma. Further the company has launched Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® approved by the FDA.

Dixon Technologies (India): Dixon Electro Appliances, a subsidiary of the company, has received approval from the government under PLI scheme for manufacturing of telecom and networking products in India. “With this, Dixon will be venturing into a new segment of telecom devices and we expect to begin production mainly for routers, modems and GPONs,” Vice Chairman and MD, Atul Lall said.

NBCC India: The company secured the total business of Rs 2,100.96 crore in September.

PNB Housing Finance: The board has decided not to proceed with a preferential issue of shares to investors led by Carlyle after the plan was delayed due to pending legal proceedings. The share subscription agreements executed with the proposed allottees have been terminated. Carlyle’s Pluto Investments S.a.r.l will be initiating the process to withdraw the open offer for PNB Housing shares made at Rs 403.22 each. India top court to hear plea on PNB Housing-Carlyle deal.

Aviation companies: From today onwards, the Ministry of Civil Aviation has allowed airlines to operate at 100 percent capacity.

M&M Forgings: MM Forgings has acquired CAFOMA Autoparts for a sum of 28 crore in cash and 5 crore of debt.

Macrotech Developers: Board to meet on Oct 21 to consider proposal to raise funds. Further the company is in talks to sell 4 lakh sq ft office building in Mumbai, according to PTI.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL